ArticleJournal of virology2026
Protective efficacy of a genetically modified attenuated vaccinia virus Tiantan strain against monkeypox virus challenge in a small animal model.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccinia virus (VACV) confers cross-protective immunity against monkeypox virus (MPXV), the causative agent of mpox, and has therefore been extensively exploited as a preventive vaccine. VACV Tiantan strain (VTT) is a second-generation smallpox vaccine used in China in the last century, and there are consistent efforts to minimize its virulence and ensure its best safety for potential clinical applications. In this study, an attenuated VACV rVTT△C12K2△A45 was constructed by deletion of gene segments related to virulence genes, host range genes, immune regulatory genes, and other functional genes from the VTT genome by genetic engineering. Attenuation characteristics of rVTT△C12K2△A45 were confirmed by smaller plaque size, lower replication capacity in various mammalian cell lines along with tests for neurotoxicity in mice, and lesion formation on rabbit skin. Immunization in BALB/c mice with rVTT△C12K2△A45 induced both anti-MPXV and anti-VACV neutralizing antibodies. Animals vaccinated with rVTT△C12K2△A45 showed lower MPXV viral loads in the lungs and genital organs compared to the non-immunized mice.IMPORTANCEThe World Health Organization declared monkeypox a "Public Health Emergency of International Concern" twice, in 2022 and 2024, respectively. Smallpox vaccines have shown efficacy in protecting against monkeypox because of the cross-protective immunity among orthopoxviruses. The vaccinia virus Tiantan strain (VTT) played a critical role in China's smallpox eradication campaign. Here, we construct an attenuated vaccinia virus by deletion of different ranges of genes in the VTT genome. This attenuated vaccinia virus replicates like its parental VTT strain in production CEF cells but is severely impaired in human-derived cells like 2BS, MRC-5, and WI-38 cells. Meanwhile, this virus shows significantly reduced virulence in small animals. Animals vaccinated with this attenuated vaccinia virus showed lower monkeypox virus (MPXV) viral loads in the lungs and genital organs compared to the non-immunized mice after MPXV challenge. Our data suggest the potential of this genetically engineered VTT strain as a MPXV vaccine candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.